BOSTON, Feb. 8, 2017 /PRNewswire/ -- DarioHealth
Corp. (NASDAQ: DRIO), a leader in digital health and mobile health
solutions and the developer of the Dario™ Blood Glucose Monitoring
System, an all-in-one diabetes meter, today announced that its
Chairman and Chief Executive Officer, Erez
Raphael, will be presenting at the annual OurCrowd's Global
Investor Summit in Jerusalem,
Israel on February 16,
2017.
In addition, DarioHealth will have a booth at the summit and
members of the team will be on hand showcasing the Dario™ Blood
Glucose Monitoring System.
Erez Raphael is slated to present
about DarioHealth's direct-to-consumer strategy and results. He is
also set to take part in some panel discussions and share the
latest insights on how DarioHealth is successfully combining
traditional tools with digital technology.
Last month, DarioHealth secured the first investment by OurCrowd
Qure, Israel's first fund focused
exclusively on digital health. DarioHealth continues expanding its
global reach, as it has already gained considerable traction with a
user-centric approach for diabetes treatment in the U.S.,
Canada, Australia and other countries. This year, the
company plans to expand into the German market.
The OurCrowd Global Investor Summit will be the world's largest
equity crowdfunding event and the biggest investor event in
Israel, with over 5,000 attendees
from over 80 countries expected to attend. The summit attracts some
200 multinational companies, venture and corporate partners,
entrepreneurs, dozens of global delegations, industry leaders and
members of the press.
For more information about the OurCrowd Global Investor Summit,
go to: http://summit.ourcrowd.com/, the content of which is not
incorporated by reference herein.
About DarioHealth Corp.
DarioHealth is a leader in digital health self-management
solutions. DarioHealth delivers the ability to combine and analyze
consumer health data to personalize treatment and advance medical
knowledge. Dario's™ smart diabetes management solution is a
platform for diabetes management that combines the Dario™ Blood
Glucose Monitoring System all-in-one blood glucose meter, native
smart phone app, website portal and a wide variety of treatment
tools to support more proactive and better informed decisions by
users living with diabetes, their doctors and healthcare
systems. Having recently launched in the largest market in
the world for glucose monitoring, U.S. sales are expected to have a
significant impact on revenues and gross margins. With marketing
clearance in Europe and the U.S.,
the Dario iOS mobile app recently launched with reimbursement in
the United Kingdom, Australia, Israel, Italy, and Canada, and has also launched in New Zealand, Netherlands, Italy, and Belgium. For more
information, visit http://mydario.investorroom.com/
About the 2017 OurCrowd Global Investor Summit
The OurCrowd Global Investor Summit is the largest equity
crowdfunding event in the world, and the biggest investor event in
the Startup Nation. Now in its third year, the Summit has
hosted thousands of investors, venture and corporate partners,
entrepreneurs, global delegations, industry leaders and members of
the press. Attendees hailing from more than 80 countries gather in
Jerusalem, the capital of the
Startup Nation, to celebrate the global community's collective
drive for innovation. Each year, attendees come from all over the
world to hear from expert industry speakers and participate in
interactive programming featuring cutting-edge technologies and the
future of crowd investing. They also have the opportunity to
support portfolio companies through significant fundraising
and making strategic business connections to help grow their
businesses.
Cautionary Note Regarding Forward-Looking Statements
This news release and the statements of representatives and
partners of DarioHealth Corp. (the "Company") related thereto
contain or may contain forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995.
Statements that are not statements of historical fact may be deemed
to be forward-looking statements. Without limiting the generality
of the foregoing, words such as "plan," "project," "potential,"
"seek," "may," "will," "expect," "believe," "anticipate," "intend,"
"could," "estimate" or "continue" are intended to identify
forward-looking statements. For example, when the Company
discusses its plans to expand into the German market, describes its
growth potential, and says that U.S. sales are expected to have a
significant impact on the Company's revenues and gross margins, it
is using forward-looking statements. Readers are cautioned that
certain important factors may affect the Company's actual results
and could cause such results to differ materially from any
forward-looking statements that may be made in this news release.
Factors that may affect the Company's results include, but are not
limited to, regulatory approvals, product demand, market
acceptance, impact of competitive products and prices, product
development, commercialization or technological difficulties, the
success or failure of negotiations and trade, legal, social and
economic risks, and the risks associated with the adequacy of
existing cash resources. Additional factors that could cause or
contribute to differences between the Company's actual results and
forward-looking statements include, but are not limited to, those
risks discussed in the Company's filings with the U.S. Securities
and Exchange Commission. Readers are cautioned that actual results
(including, without limitation, the timing for and results of the
Company's commercial and regulatory plans for Dario™) may differ
significantly from those set forth in the forward-looking
statements. The Company undertakes no obligation to publicly update
any forward-looking statements, whether as a result of new
information, future events or otherwise, except as required by
applicable law.
DarioHealth Corporate and Media Contact
Shmuel Herschberg
Marketing Director
shmuel@mydario.com
+1-800-896-9062
DarioHealth Investor Relations Contact
Hayden IR
Rob Fink / Brett
Maas
DRIO@HaydenIR.com
646-415-8972 / 646-536-7331
OurCrowd Media Contact:
Leah Stern
OurCrowd Communications Director
leah@ourcrowd.com
+44-747-0196-826
+972-54-341-4861
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/dariohealth-to-present-at-the-ourcrowd-global-investor-summit-300404149.html
SOURCE DarioHealth Corp.